CPAP and hepatocellular carcinoma: Iin addition to promoting angiogenesis, CPAP-overexpressing HCC cells are more resistant to sorafenib, the antiangiogenesis drug, treatment (Fig. 5g); in contrast, knocked-down expression of CPAP enhances the cytotoxicity effect of sorafenib (Supplementary Fig. S13).